SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

by Tomás Pascual, Tomás Pascual, Tomás Pascual, Mafalda Oliveira, Mafalda Oliveira, Mafalda Oliveira, Eva Ciruelos, Eva Ciruelos, Meritxell Bellet Ezquerra, Meritxell Bellet Ezquerra, Meritxell Bellet Ezquerra, Cristina Saura, Cristina Saura, Cristina Saura, Joaquin Gavilá, Joaquin Gavilá, Sonia Pernas, Sonia Pernas, Montserrat Muñoz, Montserrat Muñoz, Montserrat Muñoz, Maria J. Vidal, Maria J. Vidal, Maria J. Vidal, Mireia Margelí Vila, Mireia Margelí Vila, Juan M. Cejalvo, Juan M. Cejalvo, Blanca González-Farré, Blanca González-Farré, Blanca González-Farré, Martin Espinosa-Bravo, Josefina Cruz, Francisco Javier Salvador-Bofill, Juan Antonio Guerra, Ana María Luna Barrera, Miriam Arumi de Dios, Stephen Esker, Pang-Dian Fan, Olga Martínez-Sáez, Guillermo Villacampa, Guillermo Villacampa, Laia Paré, Juan M. Ferrero-Cafiero, Patricia Villagrasa, Aleix Prat, Aleix Prat, Aleix Prat, Aleix Prat
Published 2021-04-01